Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

Novartis India Ltd - 500672 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Dear Sirs, Please note that in terms of the applicable provisions of the SEBI Listing Regulations, the Company has received intimation regarding loss of share certificate from the following shareholder: Stop transfer date- Nov. 12, 2019 Folio No. - S001776; Name of the shareholder - Suryakant Patel Certificate No. 436789 Distinctive No. - 31923696 - 31923699 No. of shares - 4 Reason - Lost by holder The Registrar and Share Transfer Agent of the Company i.e. Link lntime India Private Limited has received a request letter from the abovementioned shareholder and have informed the Company about the same today i.e. on November 13, 2019. Further, subject to completion of required formalities by the shareholder, the Company will issue duplicate share certificate in lieu thereof.
13-11-2019
Bigul

Novartis buys Aspen's Japanese generic unit for up to 400 million euros

 Aspen Pharmacare has abandoned its dividend this year and is selling assets to pay down debt after levels moved close to breaching debt covenants
11-11-2019
Bigul

Novartis India Ltd - 500672 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 Dear Sirs, Apropos the subject matter quoted above, please find enclosed herewith the copies of the newspaper Notices in 'Financial Express' and 'Navshakti' on November 9, 2019. This is for your information and record.
11-11-2019
Bigul

Novartis India Ltd - 500672 - Financial Results For The Quarter And Half Year Ended On September 30, 2019

 Dear Sir/ Madam, Kindly note that the Board of Directors of the Company has in its meeting held today i.e. on Friday, November 8, 2019 ("said meeting"), inter alia considered and approved the Unaudited Financial Results of the Company for the quarter and half year ended on September 30, 2019. The said Meeting commenced at 11:00 a.m. and concluded at 3:00 p.m. Further, in terms of the applicable provisions of SEBI Listing Regulations, please find enclosed herewith: a.the Unaudited Financial Results; b.Limited Review Report dated November 8, 2019, issued by the Statutory Auditors of the Company with respect to the Unaudited Financial Results and taken on record by the Board of Directors of the Company. The above is for your information and the same is also available on the Company''s website i.e. www.novartis.in
08-11-2019
Bigul

Novartis India Ltd - 500672 - Outcome of Board Meeting

 Dear Sir/ Madam, Kindly note that the Board of Directors of the Company has in its meeting held today i.e. on Friday, November 8, 2019 ("said meeting"), inter alia considered and approved the Unaudited Financial Results of the Company for the quarter and half year ended on September 30, 2019. The said Meeting commenced at 11:00 a.m. and concluded at 3:00 p.m. Further, in terms of the applicable provisions of SEBI Listing Regulations, please find enclosed herewith: a.the Unaudited Financial Results; b.Limited Review Report dated November 8, 2019, issued by the Statutory Auditors of the Company with respect to the Unaudited Financial Results and taken on record by the Board of Directors of the Company. The above is for your information and the same is also available on the Company''s website i.e. www.novartis.in Thanking you
08-11-2019
Bigul

NOVARTIS INDIA LTD. - 500672 - Shareholding for the Period Ended September 30, 2019

 Novartis India Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2019. For more details, kindly Click here
22-10-2019
Bigul

NOVARTIS INDIA LTD. - 500672 - Compliance Certificate Of Novartis India Limited Under Regulation 7(3) Read With Regulation 7(2) Of The SEBI Listing Regulation For Half Year Ended On September 30, 2019.

 We hereby confirm that during the half year ended on September 30, 2019, all the activities in relation to the facility of transferring the Equity Shares of the Company, both in physical and electronic form, were duly maintained by the Registrar and Share Transfer Agent of the Company viz. Link Intime India Private Limited, registered in Category-I with the Securities and Exchange Board of India vide Registration Number: INR000004058 and having its registered Office at C - 101, 247 Park, L. B. S. Marg, Vikroli West, Mumbai - 400083. This is for your information and record.
18-10-2019
Bigul

NOVARTIS INDIA LTD. - 500672 - Compliance Certificate Obtained By Novartis India Limited From A Practising Company Secretary For The Half Year Ended On September 30, 2019, In Terms Of The Provisions Of Regulations 40(9) & (10) Of The SEBI Listing Regulations.

 Dear Sir/ Madam, Please note that in terms of the SEBI Listing Regulations, the Company has obtained a Compliance Certificate from Saraf & Associates, Company Secretaries, for the half year ended on September 30, 2019 and the same is being submitted herewith. This is for your information and record.
17-10-2019
Bigul

Novartis India Ltd - 500672 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 Dear Sir/ Madam, In reference to the above captioned subject, the certificate dated October 11, 2019 issued by the Registrar and Transfer Agent of the Company i.e. Link Intime India Private Limited, in terms of the provisions of the said Regulations, for the quarter ended on September 30, 2019 is enclosed herewith for your records as Annexure 1. This is for your information and record.
16-10-2019
Bigul

NOVARTIS INDIA LTD. - 500672 - Statement Of Investor Complaints For The Quarter Ended September 2019

 No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0110 Name of the Signatory :- Mr Trivikram Guda Designation :- Company Secretary and Compliance Officer
16-10-2019
Next Page
Close

Let's Open Free Demat Account